We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The purpose of the tests is to detect prostate cancer in the early stages, before the disease progresses. There are two common initial screening tests. Depending on the result, you may be referred to a urologist for a biopsy. These initial tests are:
- Rectal examination
- Prostate-specific antigen (PSA) blood test
The PSA blood test seeks to identify a protein in the blood that is specifically produced by prostate cells.
An elevated or rising PSA level alone does not always mean that a man has prostate cancer. PSA levels may increase with age and other benign conditions, such as benign prostatic hyperplasia or prostatitis. To diagnose prostate cancer, you will need to undergo a prostate biopsy.
Depending on the results, you may be referred to a urologist in order to undergo a magnetic resonance imaging (MRI) scan and a biopsy. This is the only way to determine the presence of a cancer.
This is another type of biopsy which uses the images obtained from the MRI scans and real-time ultrasound images. Using a computer programme, the images obtained in the ultrasound scan are fused, or merged, with those of the previously-performed prostate MRI. This allows lesions to be located with greater accuracy. Samples will be taken from the lesion and from the rest of the prostate. The prostate samples will be sent to the anatomopathologist (a specialist who analyses and studies the tissues). After analysing the samples under a microscope, they will confirm whether or not the patient has cancer. If they do have cancer, the anatomopathologist will also confirm how aggressive it is.
We suggest that you talk with your doctor to see whether or not you need to undergo a PSA blood analysis.
Together you can decide on the best way to proceed.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.